Browsing Tag
Oncology
318 posts
AstraZeneca’s IMFINZI/IMJUDO shows sustained OS in Phase 3 liver cancer study
AstraZeneca’s IMFINZI (durvalumab) combined with IMJUDO (tremelimumab-actl) has demonstrated an enduring overall survival (OS) benefit in patients with…
ALX Oncology gets EC’s orphan drug status for evorpacept in gastric cancer
ALX Oncology Holdings, an Australian immuno-oncology company focusing on CD47 checkpoint pathway blocking therapies, declared a significant milestone…
Natco Pharma wins FDA approval for generic colorectal cancer drug
Indian pharmaceutical firm Natco Pharma has gained the US Food and Drug Administration (FDA)’s final approval for its…
MEDiC Life Sciences, Bristol Myers Squibb to advance discovery of tumor targets
MEDiC Life Sciences, a biotech startup based in Silicon Valley, has announced a research collaboration with pharmaceutical giant…
Massive Bio, The Oncology Institute partner to revolutionize cancer treatment
Massive Bio, a healthcare technology company specializing in personalized treatment solutions for cancer patients, has announced a non-exclusive…
Invivoscribe, Complete Genomics to develop biomarker tests for oncology research
Invivoscribe and Complete Genomics have announced a partnership aimed at developing and commercializing biomarker tests on the latter’s…
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA)…
Hanx Biopharmaceuticals set to begin US clinical trial of HX009 in lymphoma
Hanx Biopharmaceuticals (HanxBio) has obtained approval from the US Food and Drug Administration (FDA) for its investigational new…
Genmab gets EPKINLY FDA approval for diffuse large B-cell lymphoma
Danish biotech company Genmab has secured accelerated approval for EPKINLY (epcoritamab-bysp) from the US Food and Drug Administration…
LaNova Medicines, AstraZeneca sign $600m worth licensing deal for LM-305
LaNova Medicines has signed an exclusive license deal worth over $600 million for its pre-clinical stage antibody drug…